Since BC exhibits cellular heterogeneity in ER expression (Fig. 5a, b), we categorized the BC cells from our PDX study as ER-low and ER-high and analyzed the impact of fulvestrant, capecitabine and the combination on these two sub-populations (Fig. 5c). Here, ESR1 is linked to breast cancer.